Patients with multiple myeloma (MM) and chronic renal failure have generally been excluded from myeloablative therapy programs followed by hematopoietic stem cell support because of the potential increase in transplant-related morbidity and mortality. We here report our experience treating six MM patients with moderate to severe renal insufficiency, with autologous stem cell transplantation. One of these patients required chronic hemodialysis since the diagnosis of MM was made. 
Introduction
Renal failure occurs in approximately 20-30% of patients with multiple myeloma (MM) at diagnosis. 1 It is more frequently associated with urinary excretion of monoclonal light chains and it can be precipitated by several factors, including hypercalcemia and/or use of non-steroidal anti-inflammatory drugs to control bone pain. Reduction in tumor cell mass following successful induction chemotherapy and adequate supportive care are generally combined to produce a significant improvement in renal function. 2 However, half of the patients do not recover and 10% of them will subsequently require chronic hemodialysis. 3 High-dose therapy requiring autologous hematopoietic stem cell support is now considered the preferable therapeutic approach for younger MM patients as a higher complete remission rate and a longer survival have been demonstrated in comparison to conventional chemotherapy. 4, 5 However, patients with renal failure have generally been excluded from (sub)myeloablative therapy programs, mainly due to the possible occurrence of life-threatening complications. In fact, antineoplastic drugs have a narrow therapeutic index, so that major toxicity can occur in patients with impaired renal function, owing to an increase in dose intensity that is difficult to predict. In this regard, an early study conducted in dogs with renal failure 6 demonstrated an increased hematological toxicity of melphalan related to a longer terminal half-life of the drug. A similar finding has been reported in MM patients receiving oral melphalan, 7 while in another study, the frequency of severe myelosuppression induced by oral melphalan was not related to renal function. 8 More recently, it has been emphasized that MM patients with renal failure can be safely treated with high-dose melphalan since they show a spectrum of toxicity similar to that expected in patients with normal renal function. 9 The feasibility of autologous hematopoietic stem cell transplantation in patients with MM and chronic renal failure has also been confirmed in other studies, using different conditioning regimens. [10] [11] [12] [13] Consistently with these latter observations, we here report six MM patients with chronic renal failure, one of them requiring chronic hemodialysis, who successfully received (sub)myeloablative therapy and autologous stem cell transplantation.
Patients and methods

Patient and treatment characteristics
Between April 1997 and November 1999, six consecutive patients with a confirmed diagnosis of active MM, 14 and impaired renal function, as defined by creatinine clearance Ͻ40 ml/h, were enrolled in a pilot clinical trial aimed at evaluating the feasibility and toxicity of high-dose chemotherapy and autologous stem cell transplantation (ASCT, Table 1 ). Five of these patients had renal failure at the time of diagnosis (median creatinine clearance 27 ml/h, range 5-34 ml/h; a renal biopsy revealed a picture of myeloma-cast nephropathy in three patients (Nos 1, 2 and 3) or light chain deposition disease in the remaining two (Nos 4 and 6). The last patient (No. 5) had relapsing MM at study entry and creatinine clearance was 20 ml/h. One patient (No. 4) had severe renal insufficiency which required hemodialysis three times a week; the other patients never received hemodialysis.
In four patients (Nos 1-4) ASCT was performed as part of front-line therapy which included VAD 15 remission induction chemotherapy administered for a minimum of four courses up to 11 courses, followed by collection of peripheral blood stem cells (PBSC) and subsequent transplantation. PBSC collection was accomplished using either high-dose cyclophosphamide (HD-Cy), 5.5 g/m 2 combined with G-CSF, 5 g/kg daily (patients 1-3), or G-CSF alone, 15 g/kg daily for 5 days (patient No. 4). In patient No. 6 HD-Cy (7 g/m 2 ) with subsequent stem cell collection was administered as first-line chemotherapy; as a complete response was obtained, maintenance treatment with alpha-interferon was started and ASCT was postponed until relapse, which occurred 6 years later. Similarly, patient No. 5 was enrolled in the study at the time of relapse which occurred following prior autologous transplantation of PBSC conditioned with melphalan 200 mg/m 2 . ASCT was supported with PBSC which had been collected prior to first transplant using HD-Cy (7 g/m 2 ), and G-CSF 5 g/kg daily.
Conditioning regimen
In patient Nos 1-3 and 6, high-dose chemotherapy consisted of busulfan, 12 mg/kg plus melphalan, 80 mg/m 2 . Patients with more severely impaired renal function (Nos 4 and 5) received a single dose of melphalan, 80 mg/m 2 ; in one of them (No. 4) hemodialysis was performed 2 h after melphalan infusion, according to pharmacokinetic parameters, as reported elsewhere. 12 
Assessment of tumor response
Response to therapy, both conventional and (sub)myeloablative, was assessed according to the criteria established by the Chronic Leukemia-Myeloma Task Force 14 and Bladé et al, 16 respectively. In patient No. 4 changes in urinary M protein excretion could not be reliably assessed due to oliguria, so that a higher than 50% reduction in bone marrow plasma cell infiltration on trephine biopsy, an increase in hemoglobin level, and improvement in quality of life were considered criteria for response definition.
Results
PBSC collection
All patients with renal failure at the time of PBSC collection (median creatinine clearance 36 ml/h) yielded total mononuclear cells (median = 0.79 × 10 9 /kg) and CD34 + cells (median = 5.3 × 10 6 /kg) sufficient to support the subsequent transplant procedure. As previously mentioned, in patient No. 
Pre-transplant disease status and renal function
At the time of ASCT four patients (Nos 1-4) were classified as having attained an objective response, defined as more than 50% decrease in either M protein concentration (patients 1-3) or bone marrow plasma cell infiltration (patient No. 4). The remaining two patients had relapsing MM, one of them (patient No. 5) following prior autologous PBSC transplantation and the other after first-line chemotherapy with HDCy. Pre-transplant median creatinine clearance was 28.5 ml/h (range 8-43 ml/h).
Transplant-related toxicity
All the patients showed a sustained engraftment; 500 PMN/l and 20 000 platelets/l were reached a median of 13 and 14 days after transplant, respectively. While neutropenic all the patients experienced one febrile episode, without microbiological evidence of bacterial/fungal infection. Grade III-IV WHO fever was never observed. Oral/gastrointestinal mucositis was observed in patient 1 (WHO grade III) and in patients 4 and 5 (grade IV) who required total parenteral nutrition for 6 days and intravenous morphine; on day 6 after transplant patient No. 4 also had hematemesis that promptly resolved with platelet transfusions. After hospital discharge (day 15) patient No. 3 had hyperbilirubinemia, ascites and painful hepatomegaly, and abdominal ultrasonography showed reversal of portal flow, suggestive of veno-occlusive disease (VOD); the patient underwent treatment with recombinant tissue plasminogen activator (r-TPA) 17 and the problem was promptly resolved.
Outcome of ASCT
Post-transplant assessment of tumor response (Table 2) revealed that four patients (Nos 1-3 and 5) attained more than 50% decrease in M protein concentration (55%, 75%, 83% and 55%, respectively) while in patient No. 4 complete remission was defined on the basis of disappearance of urinary M component and decrease in bone marrow plasma cell infiltration below 5% on trephine biopsy. No apparent response following ASCT could be demonstrated in the last patient who had the shortest follow-up (2 months) at the time the present analysis was performed. Two patients showed signs of disease progression 16 and 4 months after transplantation, while patient Nos 2, 4 and 6 have stable disease (16) after 26, 15 and 2 months, respectively. Patient No. 3 died from hepatic cholangiocarcinoma 7 months after transplantation, while still in remission. All the patients who responded favorably to ASCT experienced an improvement in renal function, as demonstrated by an increase in median creatinine clearance from 28.5 ml/h (pre-transplant) to 60 ml/h (posttransplant).
Discussion
In recent years, high-dose therapy with autologous hematopoietic stem cell support has been increasingly used in MM patients. In fact, in comparison to standard therapy, better results were obtained in terms of response rate and survival duration;
4,5 furthermore, the improvement in general supportive care has made the procedure safer even for patients aged 70 or older. 18 Recently, several groups have also proposed the use of (sub)myeloablative regimens in patients with MM and renal failure. [10] [11] [12] [13] Under these unfavorable conditions, both stem cell priming and conditioning regimens should include drugs that do not undergo renal excretion; for this reason cyclophosphamide, busulfan and melphalan have been used in different studies. Cyclophosphamide, both as parent compound and as alkylating moiety, is excreted through the kidney in percentages ranging from 1 to 14%, 19 which seems to be independent of renal function. Busulfan has been employed in preparative regimens for stem cell transplantation in MM patients; 20, 21 only negligible amounts of the compound are eliminated through the kidney, as the liver is the major site of drug metabolism. 22 Concerning melphalan, data are more controversial, as several studies have suggested that pharmacokinetic parameters are related to creatinine clearance, 7, 23 while other authors demonstrated that the main route of melphalan elimination is spontaneous degradation. 24 Most reports, however, agree on the wide interindividual differences in drug metabolism. 8, 12, 23, 24 Despite these contrasting findings, melphalan is the most active drug for MM, 25, 26 and it seems thus correct to include it in high-dose therapy programs even for patients with renal failure. In this study six patients with MM and moderate to severe renal failure, all of them showing a creatinine clearance Ͻ40 ml/h, underwent autologous PBSC transplant. This cutoff value has long been considered as an exclusion criteria for enrollment in high-dose therapy programs. 27 The results that we have obtained deserve some consideration. First, PBSC collection was successfully accomplished, and cell yield was similar to that expected in patients with normal renal function. 28 Second, ASCT procedure was well tolerated in all the patients, and only one of them had a life-threatening adverse event. We have employed the combination of busulfan and melphalan as conditioning regimen for patients with less advanced renal insufficiency and, due to the low number of patients we have treated, we cannot assume that an alteration in renal function played a role in increasing the toxicity of this regimen. For patients with more advanced renal failure we chose to use melphalan alone, in order to reduce the likelihood of severe oral mucositis, a toxic side-effect that is frequently observed after using both busulfan 29 and high-dose melphalan 30 and that could possibly be worsened by an alteration in the excretion of the latter compound. It could be argued that melphalan 80 mg/m 2 is a suboptimal, non-myeloablative dose, however, hematological toxicity in the two patients with severe renal failure was almost superimposable on that observed in patients with less severe renal impairment and WHO grade IV oral mucositis was induced. This finding is in contrast to what has been previously reported, 9, 12 demonstrating a similar toxicity of melphalan in patients with normal or impaired renal function. Our preliminary data suggest caution and optimal supportive care when using high-dose melphalan in patients with MM and severe renal failure, and further studies are probably needed in order to identify the correct dose to use. Finally, it should not be overlooked that all the patients but one showed a significant antitumor response and improvement in renal function. In conclusion, even though more studies are needed in order to design the best conditioning regimen for MM patients with renal failure, autologous PBSC transplant was safe and should be further exploited in these patients.
